Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA

O Michielin; E Richtig; I Grimmelmann; C Loquai; A Forschner; C Hoeller; J Utikal; R Gutzmer; S Haferkamp; JC Hassel; Dirk Debus; M Fluck; D Goeppner; H Kehrer; R Dummer; R von Moos; J Thompson; L Milde; D Schadendorf

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA

O Michielin, E Richtig, I Grimmelmann, C Loquai, A Forschner, C Hoeller, J Utikal, R Gutzmer, S Haferkamp, JC Hassel, Dirk Debus, M Fluck, D Goeppner, H Kehrer, R Dummer, R von Moos, J Thompson, L Milde, D Schadendorf

Universitätsklinik für Dermatologie

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	249-250
Fachzeitschrift	Oncology Research and Treatment
Jahrgang	44
Publikationsstatus	Veröffentlicht - 2021

Dieses zitieren

Michielin, O., Richtig, E., Grimmelmann, I., Loquai, C., Forschner, A., Hoeller, C., Utikal, J., Gutzmer, R., Haferkamp, S., Hassel, JC., Debus, D., Fluck, M., Goeppner, D., Kehrer, H., Dummer, R., von Moos, R., Thompson, J., Milde, L., & Schadendorf, D. (2021). Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA. Oncology Research and Treatment, 44, 249-250.

@article{a57d5a93449f4727ad8c55348324bfe6,

title = "Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA",

author = "O Michielin and E Richtig and I Grimmelmann and C Loquai and A Forschner and C Hoeller and J Utikal and R Gutzmer and S Haferkamp and JC Hassel and Dirk Debus and M Fluck and D Goeppner and H Kehrer and R Dummer and {von Moos}, R and J Thompson and L Milde and D Schadendorf",

year = "2021",

language = "English",

volume = "44",

pages = "249--250",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

}

Michielin, O, Richtig, E, Grimmelmann, I, Loquai, C, Forschner, A, Hoeller, C, Utikal, J, Gutzmer, R, Haferkamp, S, Hassel, JC, Debus, D, Fluck, M, Goeppner, D, Kehrer, H, Dummer, R, von Moos, R, Thompson, J, Milde, L & Schadendorf, D 2021, 'Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA', Oncology Research and Treatment, Jg. 44, S. 249-250.

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA. / Michielin, O; Richtig, E; Grimmelmann, I et al.
in: Oncology Research and Treatment, Jahrgang 44, 2021, S. 249-250.

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA

AU - Michielin, O

AU - Richtig, E

AU - Grimmelmann, I

AU - Loquai, C

AU - Forschner, A

AU - Hoeller, C

AU - Utikal, J

AU - Gutzmer, R

AU - Haferkamp, S

AU - Hassel, JC

AU - Debus, Dirk

AU - Fluck, M

AU - Goeppner, D

AU - Kehrer, H

AU - Dummer, R

AU - von Moos, R

AU - Thompson, J

AU - Milde, L

AU - Schadendorf, D

PY - 2021

Y1 - 2021

M3 - published Abstract (Journal)

SN - 2296-5270

VL - 44

SP - 249

EP - 250

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -